Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

  1. Thiery-Vuillemin, A.
  2. de Bono, J.
  3. Hussain, M.
  4. Roubaud, G.
  5. Procopio, G.
  6. Shore, N.
  7. Fizazi, K.
  8. dos Anjos, G.
  9. Gravis, G.
  10. Joung, J.Y.
  11. Matsubara, N.
  12. Castellano, D.
  13. Degboe, A.
  14. Gresty, C.
  15. Kang, J.
  16. Allen, A.
  17. Poehlein, C.
  18. Saad, F.
Revista:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Any de publicació: 2022

Volum: 23

Número: 3

Pàgines: 393-405

Tipus: Article

DOI: 10.1016/S1470-2045(22)00017-1 GOOGLE SCHOLAR